1 / 3

Oncology Biosimilars Market Global Trends, and Forecast till 2026

Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product.<br>

rajbisen
Télécharger la présentation

Oncology Biosimilars Market Global Trends, and Forecast till 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oncology Biosimilars Market 2026 with the Current State of the Oncology Biosimilars Market 2026 with the Current State of the Industry, Major Provincial Sectors, key players such as Amgen Inc., Industry, Major Provincial Sectors, key players such as Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc. Pharmaceutical Industries Ltd., Pfizer Inc. Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market. Request Sample Copy of Research Report @ Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1305 https://www.coherentmarketinsights.com/insight/request-sample/1305 Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth of the oncology biosimilars market over the forecast period of the oncology biosimilars market over the forecast period There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

  2. North America is expected to dominate the oncology biosimilars market over the forecast period North America is expected to dominate the oncology biosimilars market over the forecast period On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF- 05280014, PF-05280586 and PF-06439535) for oncology in Phase 3. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Oncology Biosimilars Market Research Objective and Assumption • Oncology Biosimilars Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Oncology Biosimilars Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Oncology Biosimilars Market, By Regions • Oncology Biosimilars Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Oncology Biosimilars Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Oncology Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Oncology Biosimilars Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion

  3. Europe market is also expected to witness rapid growth over the forecast period. This is due to expected launch of major products in the market over the forecast period. Europe-based leading generic manufacturers such as Sandoz (a Novartis International AG’s division) and Mylan N.V. has shown interest in this field. Mylan N.V. has entered into a collaboration agreement with Biocon Limited to develop biosimilars in 2009. The duo got approval for their first biosimilar product in 2017 in U.S. and also, European Medicines Agency (EMA) has accepted resubmission for their Herceptin biosimilar in the same year. With increasing number of approved products, the oncology biosimilars market is expected to witness significant growth in the region over the forecast period. Request For Customization of Research Report @ Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1305 https://www.coherentmarketinsights.com/insight/request-customization/1305 Key players operating in the global oncology biosimilars market include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related